nach oben

Administration and Policy in Mental Health and Mental Health Services Research

Erschienen in:

04.06.2015 | Original Article

Projected Spending on Psychotropic Medications 2013–2020

verfasst von: Dominic Hodgkin, Cindy Parks Thomas, Peggy L. O’Brien, Katharine Levit, John Richardson, Tami L. Mark, Kevin Malone

Erschienen in: Administration and Policy in Mental Health and Mental Health Services Research | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Spending on psychotropic medications has grown rapidly in recent decades. Using national data on drug expenditures, patent expirations, future drug development and expert interviews, we project that spending will grow more slowly over the period 2012–2020. The average annual increase is projected to be just 3.0 % per year, continuing the steady deceleration in recent years. The main drivers of this expected deceleration include slower development of new drugs, upcoming patent expirations which will lower prices, and payers’ growing ability to manage utilization and promote generic use. The slowdown will relieve some cost pressures on payers, particularly Medicare and Medicaid.

Nur mit Berechtigung zugänglich

The six experts were: Donald Goff, M.D. (New York University), Steven E. Hyman, M.D. (Harvard University), Raye Z. Litten, Ph.D. (National Institute on Alcohol Abuse and Alcoholism), Andrew A. Nierenberg, M.D. (Massachusetts General Hospital), William Potter (National Institute of Mental Health), Eric C. Strain, M.D., (Johns Hopkins Bayview Medical Center).

The concept of generic entry here is admittedly somewhat simplified, as we do not distinguish markets with “Paragraph 4 challenges,” where a single generic manufacturer obtains generic exclusivity for an initial period of 180 days. In these markets, one would expect a less dramatic differential between the introductory generic price and the brand price and possibly slower growth of the generic share. However, these issues would be difficult to address in data summarized by year, and they are unlikely to affect long-range predictions.

Aitken, M. L., Berndt, E. R., Bosworth, B., Cockburn, I. M., Frank, R., Kleinrock, M., & Shapiro, B. T. (2013). The regulation of prescription drug competition and market responses: Patterns in prices and sales following loss of exclusivity NBER Working Paper Series. Cambridge, MA: National Bureau of Economic Research

Berndt, E. R., & Aitken, M. L. (2011). Brand loyalty, generic entry and price competition in pharmaceuticals in the quarter century after the 1984 Waxman-Hatch legislation. International Journal of the Economics of Business, 18(2), 177–201.CrossRef

Center for Medicare and Medicaid Services (2013). National health expenditure (NHE) Amounts by type of expenditure and source of funds: Calendar years 1965–2022. Retrieved May 26, 2015, from http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsProjected.html.

Centers for Medicare & Medicaid Services. (2012). Medicaid program: Eligibility changes under the Affordable Care Act of 2010 (CMS-2349-F). Baltimore, MD: Centers for Medicare & Medicaid Services. Retrieved May 26, 2015, from http://www.medicaid.gov/AffordableCareAct/downloads/CMS-2349-F-RegulatoryImpactAnalysis.pdf.

Centers for Medicare & Medicaid Services. (2014). Accuracy analysis of the short-term (11-year) national health expenditure projections. Retrieved July 04, 2014, from http://www.cms.gov/NationalHealthExpendData/downloads/ProjectionAccuracy.pdf

Congressional Budget Office. (2013). Table 1. CBO’s May 2013 Estimate of the Affordable Care Act on Health Insurance Coverage. Washington, D.C.: Congressional Budget Office. Retrieved May 26, 2015, from https://www.cbo.gov/sites/default/files/cbofiles/attachments/43900-2013-05-ACA.pdf.

Cuckler, G. A., Sisko, A. M., Keehan, S. P., Smith, S. D., Madison, A. J., Poisal, J. A., & Stone, D. A. (2013). National health expenditure projections, 2012–22: slow growth until coverage expands and economy improves. Health Affairs (Millwood), 32(10), 1820–1831. doi:10.1377/hlthaff.2013.0721.CrossRef

Donohue, J. M., Huskamp, H. A., & Zuvekas, S. H. (2009). Dual eligibles with mental disorders and Medicare part D: how are they faring? Health Affairs (Millwood), 28(3), 746–759. doi:10.1377/hlthaff.28.3.746.CrossRef

Druss, B. G., Marcus, S. C., Olfson, M., & Pincus, H. A. (2004). Listening to generic Prozac: Winners, losers and sideliners. Health Affairs, 23(5), 210–216. doi:10.1377/hlthaff.23.5.210.CrossRefPubMed

Finkelstein, A., Taubman, S., Wright, B., Bernstein, M., Gruber, J., Newhouse, J., & Oregon Health Study Group. (2012). The oregon health insurance experiment: Evidence from the first year. Quarterly Journal of Economics, 127(3), 1057–1106.CrossRefPubMedPubMedCentral

Foster, R. (2010). Estimated financial effects of the “Patient Protection and Affordable Care Act”, as amended. Baltimore, MD: Centers for Medicare & Medicaid Services. Retrieved Apr 22, 2010, from http://www.cms.gov/Research-Statistics-Data-and-Systems/Research/ActuarialStudies/Downloads/PPACA_2010-04-22.pdf.

Goplerud, E., & Center, National Opinion Research. (2013). Consistency of large employer and group health plan benefits with requirements of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Chicago: University of Chicago.

Hartman, M., Martin, A. B., Benson, J., & Catlin, A. (2013). National health spending in 2011: overall growth remains low, but some payers and services show signs of acceleration. Health Affairs (Millwood), 32(1), 87–99. doi:10.1377/hlthaff.2012.1206.CrossRef

Ibrahim, H. M., & Tamminga, C. A. (2012). Treating impaired cognition in schizophrenia. Current Pharmaceutical Biotechnology, 13(8), 1587–1594.CrossRefPubMed

Levit, K. R., Mark, T. L., Coffey, R. M., Frankel, S., Santora, P., Vandivort-Warren, R., & Malone, K. (2013). Federal spending on behavioral health accelerated during recession as individuals lost employer insurance. Health Affairs, 32(5), 952–962. doi:10.1377/hlthaff.2012.1065.CrossRefPubMed

Mark, T. L., Kassed, C., Levit, K., & Vandivort-Warren, R. (2012). An analysis of the slowdown in growth of spending for psychiatric drugs, 1986–2008. Psychiatric Services, 63(1), 13–18. doi:10.1176/appi.ps.201100564.CrossRefPubMed

Mark, T. L., Levit, K. R., Yee, T., & Chow, C. M. (2014). Spending on mental and substance use disorders projected to grow more slowly than all health spending through 2020. Health Affairs (Millwood), 33(8), 1407–1415. doi:10.1377/hlthaff.2014.0163. Research Support, U.S. Gov’t, P.H.S..CrossRef

Mark, T. L., Wier, L. M., Malone, K., Penne, M., & Cowell, A. J. (2015). National estimates of behavioral health conditions and their treatment among adults newly insured under the ACA. Psychiatric Services, 66, 426–429. doi:10.1176/appi.ps.201400078.CrossRefPubMed

Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012). Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Molecular Psychiatry, 17(12), 1206–1227. doi:10.1038/mp.2012.47.CrossRefPubMed

Moghaddam, B., & Javitt, D. (2012). From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology, 37(1), 4–15. doi:10.1038/npp.2011.181.CrossRefPubMedPubMedCentral

Murrough, J. W., & Charney, D. S. (2012). Is there anything really novel on the antidepressant horizon? Current Psychiatry Reports, 14(6), 643–649. doi:10.1007/s11920-012-0321-8.CrossRefPubMedPubMedCentral

O’Brien, P. L., Thomas, C. P., Hodgkin, D., Levit, K. R., & Mark, T. L. (2014). The diminished pipeline for medications to treat mental health and substance use disorders. Psychiatric Services, 65(12), 1433–1438. doi:10.1176/appi.ps.201400044.CrossRefPubMedPubMedCentral

Saha, A., Grobowski, H., Birnbaum, H., Greenberg, P., & Bizan, O. (2006). Generic competition in the US pharmaceutical industry. International Journal of the Economics of Business, 13(1), 15–38.CrossRef

Substance Abuse and Mental Health Services Administration. (2012). Results from the 2011 national survey on drug use and health: Mental health findings. Rockville, MD: Substance Abuse and Mental Health Services Administration. HHS Publication No. (SMA) 12-4725.

Substance Abuse and Mental Health Services Administration. (2013). National expenditures for mental health services and substance abuse treatment, 1986–2009. Rockville, MD: SAMHSA.

Substance Abuse and Mental Health Services Administration. (2014). Projections of national expenditures for treatment of mental and substance use disorders, 2010–2020. Rockville, MD: Substance Abuse and Mental Health Services Administration.

Thomas, C., Hodgkin, D., Wallack, S., Martin, T., Ritter, G., & Mark, T. (2007). Mental health and substance abuse treatment prescription drugs: Lessons from a period of high spending growth. Journal of Pharmaceutical Finance Economics and Policy, 16(3), 67.

U.S. Census Bureau. (2011). Downloadable files containing information from the 2011 American Community Survey. Washington, D.C.: U.S. Census Bureau. Retrieved May 26, 2015, from http://www.census.gov/acs/www/data_documentation/2011_release/.

Titel: Projected Spending on Psychotropic Medications 2013–2020
verfasst von: Dominic Hodgkin
Cindy Parks Thomas
Peggy L. O’Brien
Katharine Levit
John Richardson
Tami L. Mark
Kevin Malone
Publikationsdatum: 04.06.2015
Verlag: Springer US
Erschienen in: Administration and Policy in Mental Health and Mental Health Services Research / Ausgabe 4/2016
Print ISSN: 0894-587X
Elektronische ISSN: 1573-3289
DOI: https://doi.org/10.1007/s10488-015-0661-x

Neu im Fachgebiet Psychiatrie

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Projected Spending on Psychotropic Medications 2013–2020

Abstract

Neu im Fachgebiet Psychiatrie

Wartezeit nicht kürzer, aber Arbeit flexibler

Chirurginnen und Chirurgen sind stark suizidgefährdet

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Psychiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

The Healthy Immigrant Effect on Mental Health: Determinants and Implications for Mental Health Policy in Spain

A Comparison of Benefit Limits in Mental Health

Patient Activation and Mental Health Care Experiences Among Women Veterans

Does the Hospital Predict Readmission? A Multi-level Survival Analysis Approach

Online Information Searches and Help Seeking for Mental Health Problems in Urban China

Socio-contextual Determinants of Research Evidence Use in Public-Youth Systems of Care

Neu im Fachgebiet Psychiatrie

Wartezeit nicht kürzer, aber Arbeit flexibler

Chirurginnen und Chirurgen sind stark suizidgefährdet

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Psychiatrie